BR112018074838A2 - anticorpos anti-ige - Google Patents

anticorpos anti-ige

Info

Publication number
BR112018074838A2
BR112018074838A2 BR112018074838-2A BR112018074838A BR112018074838A2 BR 112018074838 A2 BR112018074838 A2 BR 112018074838A2 BR 112018074838 A BR112018074838 A BR 112018074838A BR 112018074838 A2 BR112018074838 A2 BR 112018074838A2
Authority
BR
Brazil
Prior art keywords
ige
improved
antigen binding
binding agents
receptor
Prior art date
Application number
BR112018074838-2A
Other languages
English (en)
Inventor
Adams Ralph
Allen Ceska Thomas
Marie Davies Anna
James Henry Alistair
Liu Xiaofeng
Michael Mcdonnell James
John Sutton Brian
Katarzyna WESTWOOD Marta
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112018074838A2 publication Critical patent/BR112018074838A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)

Abstract

a presente invenção se refere à área de anticorpos anti-ige e agentes de ligação de antígeno melhorados, e composições dos mesmos, que alvejam ige, por exemplo: para o uso no tratamento de distúrbios causados pela ige (tais como respostas alérgicas, ou certas respostas autoimunes); e, em particular, distúrbios causados pela interação de ige com o receptor fceri. em particular, esta invenção se refere aos anticorpos anti-ige e agentes de ligação de antígeno melhorados relacionados com novos mutantes de omalizumab (xolair®). os anticorpos anti-ige e agentes de ligação de antígeno melhorados da invenção podem ter afinidade melhorada para ige e/ou uma interação melhorada com o domínio ce2 da ige e/ou um epítopo modificado melhorado na ige (por exemplo envolvendo ainda mais o domínio ce2 da ige) e/ou a capacidade para dissociar ige do receptor de fceri por exemplo nas concentrações farmaceuticamente relevantes. em um aspecto, tratamentos melhorados ou novos para distúrbios mediados pela ige são divulgados em que a ige é alvejada (por exemplo ige livre e/ou ige complexada com o receptor fceri).
BR112018074838-2A 2016-06-10 2017-06-08 anticorpos anti-ige BR112018074838A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1610198.2 2016-06-10
GBGB1610198.2A GB201610198D0 (en) 2016-06-10 2016-06-10 Anti-ige antibodies
GB1702435.7 2017-02-15
GBGB1702435.7A GB201702435D0 (en) 2016-06-10 2017-02-15 Anti-ige antibodies
PCT/EP2017/063916 WO2017211928A1 (en) 2016-06-10 2017-06-08 ANTI-IgE ANTIBODIES

Publications (1)

Publication Number Publication Date
BR112018074838A2 true BR112018074838A2 (pt) 2019-03-26

Family

ID=56894897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074838-2A BR112018074838A2 (pt) 2016-06-10 2017-06-08 anticorpos anti-ige

Country Status (26)

Country Link
US (2) US11214627B2 (pt)
EP (1) EP3468995A1 (pt)
JP (2) JP7164439B2 (pt)
KR (1) KR102456813B1 (pt)
CN (1) CN109379892B (pt)
AR (1) AR108707A1 (pt)
AU (1) AU2017277600A1 (pt)
BR (1) BR112018074838A2 (pt)
CA (1) CA3027120A1 (pt)
CL (2) CL2018003556A1 (pt)
CO (1) CO2018013006A2 (pt)
EA (1) EA201990004A1 (pt)
EC (1) ECSP19001438A (pt)
GB (2) GB201610198D0 (pt)
IL (2) IL309516A (pt)
MA (1) MA45231A (pt)
MX (1) MX2018014761A (pt)
PE (1) PE20190212A1 (pt)
PH (1) PH12018502574A1 (pt)
SG (1) SG11201810199WA (pt)
TN (1) TN2018000423A1 (pt)
TW (1) TW201802114A (pt)
UA (1) UA126468C2 (pt)
UY (1) UY37290A (pt)
WO (1) WO2017211928A1 (pt)
ZA (2) ZA201807822B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
EP3774925A1 (en) 2018-04-13 2021-02-17 Institut national de la santé et de la recherche médicale (INSERM) Fc-engineered anti-human ige antibodies and methods of use
CA3116091A1 (en) * 2018-10-16 2020-04-23 UCB Biopharma SRL Method for the treatment of myasthenia gravis
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
AU2019456113A1 (en) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用
US20230183810A1 (en) * 2020-05-04 2023-06-15 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
WO2022061236A1 (en) * 2020-09-21 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University High affinity anti-ige antibodies
CN118119641A (zh) * 2021-10-12 2024-05-31 联合生物制药股份有限公司 Ige调节的疾病的治疗
WO2023070502A1 (zh) * 2021-10-29 2023-05-04 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
WO2024003376A1 (en) * 2022-07-01 2024-01-04 Alk-Abelló A/S Displacers of ige-fceri
CN116143932A (zh) * 2022-12-07 2023-05-23 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN116754773B (zh) * 2023-05-15 2024-06-07 江南大学 一种免疫球蛋白e的检测试剂盒

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JP2584613B2 (ja) 1985-03-30 1997-02-26 バリベ、マール 組換えｄｎａ技術によってｄｎａ、ｒｎａ、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ATE233813T1 (de) 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
ZA971607B (en) * 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO1999038531A1 (en) * 1998-01-29 1999-08-05 Tanox, Inc. TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2000072879A1 (en) * 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
EP2155238B1 (en) * 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
JP6139885B2 (ja) 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド 治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
KR102048382B1 (ko) * 2011-11-11 2019-11-25 유씨비 바이오파마 에스피알엘 알부민 결합 항체 및 이의 결합 단편
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
US20150140608A1 (en) 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN104987412A (zh) 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgE螯合物及其制备方法和应用
WO2017044664A1 (en) * 2015-09-11 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Omalizumab resistant ige variants and their use in anti-ige therapy
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
CN109379892A (zh) 2019-02-22
IL309516A (en) 2024-02-01
TN2018000423A1 (en) 2020-06-15
CA3027120A1 (en) 2017-12-14
KR20190017949A (ko) 2019-02-20
AU2017277600A2 (en) 2019-01-17
CN109379892B (zh) 2023-07-04
IL263452B1 (en) 2024-01-01
TW201802114A (zh) 2018-01-16
US20220235146A1 (en) 2022-07-28
MX2018014761A (es) 2019-04-25
US11214627B2 (en) 2022-01-04
UA126468C2 (uk) 2022-10-12
WO2017211928A1 (en) 2017-12-14
AR108707A1 (es) 2018-09-19
RU2019100034A3 (pt) 2020-11-20
JP2019522470A (ja) 2019-08-15
CL2021002696A1 (es) 2022-06-03
ECSP19001438A (es) 2019-01-31
US20190144565A1 (en) 2019-05-16
UY37290A (es) 2018-01-31
IL263452B2 (en) 2024-05-01
EA201990004A1 (ru) 2019-06-28
PE20190212A1 (es) 2019-02-07
PH12018502574A1 (en) 2019-10-28
SG11201810199WA (en) 2018-12-28
GB201610198D0 (en) 2016-07-27
AU2017277600A1 (en) 2019-01-03
JP2023021974A (ja) 2023-02-14
GB201702435D0 (en) 2017-03-29
EP3468995A1 (en) 2019-04-17
ZA201807822B (en) 2020-05-27
ZA202000803B (en) 2021-08-25
JP7164439B2 (ja) 2022-11-01
MA45231A (fr) 2021-05-05
RU2019100034A (ru) 2020-07-13
CL2018003556A1 (es) 2019-04-05
KR102456813B1 (ko) 2022-10-20
IL263452A (en) 2019-01-31
CO2018013006A2 (es) 2019-04-30

Similar Documents

Publication Publication Date Title
BR112018074838A2 (pt) anticorpos anti-ige
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
BR112018075663A2 (pt) compostos e composições para a inibição da atividade de shp2
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112017012944A2 (pt) ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza?
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
BR112014009030A2 (pt) anticorpo de ligação a antígenos múltiplos estável
BR112014008764A8 (pt) Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide
BRPI0708101B8 (pt) anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico
BR112013003262A2 (pt) anticorpos melhorados da classe igg4.
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
BR112013009984A2 (pt) anticorpos para tratamento do hiv
BR112018002877A2 (pt) anticorpos anti-receptor ccr7 humanizados
BR112014008804A2 (pt) suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112014027991A2 (pt) agentes para neutralização de influenza
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
BR112014006929A2 (pt) agentes anti-fator de necrose tumoral-alfa e seus usos
BR112015029300A2 (pt) Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit
BR112012024786A2 (pt) anticorpos humanizados il-25
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]